Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension

Five-year data from the PROUD-PV/CONTINUATION-PV studies, presented during the 2020 ASH Annual Meeting, demonstrated that among patients with polycythemia vera, 81.8% of those receiving ropeginterferon alpha-2b maintained hematocrit <45% without the need for phlebotomy, compared with 63.2% of the control group (p=0.01). Major thromboembolic adverse events were experienced in 4.2% compared with 6.6% of patients, respectively.